# Regulation of Ferroptosis in Human Macrophage by Nitric Oxide Donors

**Authors:** I.I. Vlasova, M.D. Yurkanova, A.A. Zolotopup, T.O. Klyucherev, P.S. Timashev

PMC · DOI: 10.17691/stm2025.17.3.04 · 2025-06-30

## TL;DR

This study explores how nitric oxide donors can regulate ferroptosis, a type of cell death, in human macrophages derived from THP-1 cells.

## Contribution

The novel finding is that DTPA NONOate, a nitric oxide donor with a longer half-life, can inhibit ferroptosis in THP-1 macrophages.

## Key findings

- RSL3 and ML-162 dose-dependently induce ferroptosis in THP-1 macrophages.
- DTPA NONOate inhibits ferroptosis, while DEA NONOate has no effect.
- Ferroptosis in THP-1 macrophages is a slow process beginning ~5 hours after inducer addition.

## Abstract

Ferroptosis is a programmed form of cell death in which iron-dependent lipid peroxidation is the main feature. Macrophages are the major cells of the immune system, they function in a pro-oxidative environment, so the study of their susceptibility to ferroptosis and the search for approaches to its regulation are important.

The aim of the study was to investigate ferroptosis in macrophages differentiated from THP-1 myeloid leukemia cells and to compare the effect of NO donors with different half-lives on the degree of ferroptosis development.

RSL3 and ML-162, inhibitors of glutathione peroxidase 4 (GPX4), and erastin, an inhibitor of cystine/ glutamate transport, were used to induce ferroptosis in THP-1 macrophages. The progression of ferroptosis was monitored using three independent methods: reduction of Alamar blue by live cells, measurement of lactate dehydrogenase in the medium, and the LIVE/DEAD assay. Ferroptotic cell death was proven by using the specific inhibitor ferrostatin-1 and by detecting lipid oxidation in cells using the BODIPY 581/591 C11 fluorescent probe.

RSL3 and ML-162 dose-dependently induced ferroptosis in cells. THP-1 macrophage ferroptosis is a slow process and begins ~5 h after inducer addition. Erastin was a weak ferroptosis inducer; however, it enhanced ferroptosis induced by GPX4 inhibitors. We compared the ability of two NO donors with different half-lives to affect THP-1 macrophage ferroptosis: DEA NONOate (2 min) and DTPA NONOate (3 h). Donors were added either once after the inducer at a concentration of 100–120 μM or repeatedly until reaching the final concentration. DEA had no effect on THP-1 macrophage ferroptosis, whereas DPTA completely inhibited ferroptosis.

DTPA, being an NO donor with a half-life of 3 h at 37°С, can be used to inhibit ferroptosis in THP-1 macrophages, which develops within 17–19 h. Therefore, there are mechanisms of prolongation of NO action in cells that should be studied to use NO donors for regulation of cellular ferroptosis.

## Linked entities

- **Proteins:** GPX4 (glutathione peroxidase 4), GPX4 (glutathione peroxidase 4)
- **Chemicals:** RSL3 (PubChem CID 1750826), ML-162 (PubChem CID 3689413), erastin (PubChem CID 11214940), ferrostatin-1 (PubChem CID 4068248), BODIPY 581/591 C11 (PubChem CID 9914060), DEA NONOate (PubChem CID 6331148)

## Full-text entities

- **Genes:** GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}
- **Diseases:** myeloid leukemia (MESH:D007951)
- **Chemicals:** NO (MESH:D009614), Nitric Oxide (MESH:D009569), DTPA (MESH:D004369), DEA NONOate (MESH:C084012), ferrostatin-1 (MESH:C573944), Erastin (MESH:C477224), cystine (MESH:D003553), iron (MESH:D007501), BODIPY 581/591 C11 (-), Alamar blue (MESH:C005843), lipid (MESH:D008055), glutamate (MESH:D018698)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12261289/full.md

---
Source: https://tomesphere.com/paper/PMC12261289